Evidence for efficacy is based on the results from the IRAKLIA, IZALCO and IsaSocut studies
Home World News FDA Approves Isatuximab-irfc for Subcutaneous Injection for Multiple Myeloma Indications
Evidence for efficacy is based on the results from the IRAKLIA, IZALCO and IsaSocut studies
